Generic Medicine Info
Indications and Dosage
Adult: 10-20 mg once-bid, increased by 10-20 mg every 3 or 4 days according to severity of condition. Maintenance: 20-120 mg daily.
Phaeochromocytoma, heart failure.
Special Precautions
Renal impairment, coronary or cerebral arteriosclerosis, asthma, history of peptic ulceration, pregnancy. Abrupt cessation may lead to rebound hypertension.
Adverse Reactions
Postural hypotension, failure of ejaculation, fluid retention, nasal decongestion, headache, diarrhoea, drowsiness.
Drug Interactions
Adrenaline, amfetamine, other sympathomimetics, TCAs, MAOIs, phenothiazine derivatives and related antipsychotics, oral contraceptives, digoxin or other digitalis derivatives, thiazide diuretics, other antihypertensives, levodopa, alcohol.
Description: Debrisoquine acts by selectively inhibiting transmission in postganglionic adrenergic nerves. It acts mainly by preventing the release of noradrenaline at nerve endings. It does not prevent the catecholamine secretion by the adrenal medulla.
Onset: 4-10 hr.
Duration: 9-24 hr.
Absorption: Rapidly absorbed from the GI tract.
Metabolism: Main metabolite: 4-hydroxydebrisoquine.
MIMS Class
Other Antihypertensives
Disclaimer: This information is independently developed by MIMS based on Debrisoquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in